Peptide receptors in gut endocrine tumours

Bailliere's Clinical Gastroenterology

Volumn 10, Issue 4, 1996, Pages 571-587

  De Herder, Wouter W ^a   Hofland, Leo J ^a   Van Der Lely, Aart Jan ^a   Lamberts, Steven W J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OCTAPEPTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

CARCINOID; ENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; PANCREAS ISLET CELL TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; REVIEW;

EID: 0030430120     PISSN: 09503528     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3528(96)90014-7     Document Type: Article

References (53)

1. Ahlman H, Wangberg B & Nilsson O (1993) Growth regulation in carcinoid tumors. Endocrinology and Metabolism Clinics of North America 22: 889-915.
2. Brazeau P, Vale W, Burgus R et al (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77-79.
3. Buscail L, Esteve JP, Saint-Laurent N et al (1995) Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proceedings of the National Academy of Sciences of the USA 92: 1580-1584.
4. Evers BM, Townsend CM Jr, Upp JR et al (1991) Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 101: 303-311.
5. van Hagen PM, Krenning EP, Kwekkeboom DJ et al (1994) Somatastatin and the immune and haematopoetic system; a review. European Journal of Clinical Investigation 24: 91-99.
6. Hennig IM, Laissue JA, Horisberger U & Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. International Journal of Cancer 61: 786-792.
7. Hofland LJ & Lamberts SWJ (1996) Somatostatin receptors and disease: role of receptor subtypes. In Baillière's Clinical Endocrinology and Metabolism, vol. 10, pp 163-176. London: Baillière Tindall.
8. Hofland LJ, van Koetsveld PM, Waaijers M et al (1994) Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology 134: 301-306.
9. 3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology 136: 3698-3706.
10. Hofland LJ, Visser-Wisselaar HA & Lamberts SW (1995b) Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Biochemical Pharmacology 50: 287-297.
11. Hoyer D, Bell GI, Berelowitz M et al (1995) Classification and nomenclature of somatostatin receptors. Trends in Pharmacological Sciences 16; 86-88.
12. Ishizuka J, Beauchamp RD, Evers BM et al (1992) Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells. Biochemical and Biophysical Research Communications 185: 577-581.
13. Jamar F, Fiasse R, Leners N & Pauwels S (1995) Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. Journal of Nuclear Medicine 36: 542-549.
14. 1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. European Journal of Endocrinology 131: 577-581.
15. 3]-octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine 20: 716-731.
16. Krenning EP, Kwekkeboom DJ, Oei HY et al (1994a) Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Annals of the New York Academy of Sciences 733: 416-424.
17. 1]-octreotide. A case history. Annals of the New York Academy of Sciences 733: 496-506.
18. Krenning EP, Kwekkeboom DJ, Pauwels S et al (1995) Somatostatin receptor scintigraphy. Nuclear Medicine Annual 1-50.
19. Kubota A, Yamada Y, Kagimoto S et al (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. Journal of Clinical Investigation 93: 1321-1325.
20. 111In-octreotide scintigraphy. Clinical Endocrinology 39: 239-243.
21. Kwekkeboom DJ, Krenning EP, Bakker WH et al (1993b) Somatostatin analogue scintigraphy in carcinoid tumours. European Journal of Nuclear Medicine 20: 283-292.
22. Lamberts SW (1988) The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocrine Reviews 9: 417-436.
23. Lamberts SW, Pieters GF, Metselaar HJ et al (1988) Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Acta Endocrinologica Copenhagen 119: 561-566.
24. Lamberts SWJ, Hofland LJ, van Koetsveld PM et al (1990) Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. Journal of Clinical Endocrinology and Metabolism 71: 566-574.
25. Lamberts SW, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews 12: 450-482.
26. Lamberts SW, Hofland LJ, de Herder WW et al (1993) Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Frontiers of Neuroendocrinology, 14: 27-55.
27. Lamberts SWJ, van der Lely AJ, de Herder WW & Hofland LJ (1996) Octreotide. New England Journal of Medicine 334: 246-254.
28. Lebtahi R, Cadiot G, Sarda L et al (1994) Clinical interest of Octreoscan 111 scintigraphy in gastroenteropancreatic tumors. Journal of Nuclear Medicine 35: 96P (abstract).
29. Liebow C, Reilly C, Serrano M & Schally AV (1989) Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proceedings of the National Academy of Sciences of the USA 86: 2003-2007.
30. McEntee GP, Nagorney DM, Kvols LK et al (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108: 1091-1096.
31. Moertel CG, Kvols LK, O'Connell MJ & Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227-232.
32. Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocinfluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 326: 519-523.
33. Moertel CG, Johnson CM, McKusick MA et al (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Annals of Internal Medicine 120: 302-309.
34. Oberg K (1993) The use of chemotherapy in the management of neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 22: 941-952.
35. Oberg K, Eriksson B & Janson ET (1994) The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Annals of the New York Academy of Sciences 733: 471-478.
36. Pradayrol L, Jornvall H, Mutt V & Ribet A (1980) N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Letters 109: 55-58.
37. Reisine T & Bell GI (1995) Molecular properties of somatostatin receptors. Neuroscience 67: 777-790.
38. Reubi JC (1993) The role of peptides and their receptors as tumor markers. Endocrinology and Metabolism Clinics of North America 22: 917-939.
39. Reubi JC (1995a) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. Journal of Nuclear Medicine 36: 1825-1835.
40. Reubi JC (1995b) In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. Journal of Nuclear Medicine 36: 1846-1853.
41. Reubi JC & Laissue JA (1995) Multiple actions of somatostatin in neoplastic disease. Trends in Pharmacological Science 16: 110-115.
42. Reubi JC, Kvols LK, Waser B et al (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Research 50: 5969-5977.
43. Reubi JC, Krenning E, Lamberts SW & Kvols L(1992a) In vitro detection of somatostatin receptors in human tumors. Metabolism 41: 104-110.
44. Reubi JC, Laissue J, Krenning E & Lamberts SW (1992b) Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. Journal of Steroid Biochemistry and Molecular Biology 43: 27-35.
45. Reubi JC, Horisberger U & Laissue J (1994a) High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? International Journal of Cancer 56: 681-688.
46. Reubi JC, Laissue J, Waser B et al (1994b) Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Annals of the New York Academy of Sciences 733: 122-137.
47. Reubi JC, Schaer JC, Waser B & Mengod G (1994c) Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Research 54: 3455-3459.
48. Schinner WJ, O'Dorisio TM, Schirmer TP et al (1993) Intraoperative localization of neuroendocrine tumors with 1251-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surgery 114: 745-751.
49. Srikant CB (1995) Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. Biochemical and Biophysical Research Communications 209: 400-406.
50. Srkalovic G, Cai RZ & Schally AV (1990) Evaluation of receptors for somatostatin in various tumors using different analogs. Journal of Clinical Endocrinology and Metabolism 70: 661-669.
51. Vikic-Topic S, Raisch KP, Kvols LK & Vuk-Pavlovic S (1995) Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. Journal of Clinical Endocrinology and Metabolism 80: 2974-2979.
52. Virgolini I, Raderer M, Kurtaran A et al (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. New England Journal of Medicine 331: 1116-1121.
53. Virgolini I, Kurtaran A, Raderer M et al (1995) Vasoactive intestinal peptide receptor scintigraphy. Journal of Nuclear Medicine 36: 1732-1739.